BlackRock, Inc. 13D and 13G filings for Nektar Therapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 15,969,345 8.700% | 0 (Unchanged) | Filing |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 15,969,345 8.700% | 7,365,023 (+85.60%) | Filing |
| 2023-07-07 4:35 pm Sale | 2023-06-30 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 8,604,322 4.500% | -9,696,352 (-52.98%) | Filing |
| 2023-05-05 11:52 am Sale | 2023-04-30 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 18,300,674 9.700% | -17,627,419 (-49.06%) | Filing |
| 2023-01-23 3:52 pm Purchase | 2022-12-31 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 35,928,093 19.100% | 9,256,290 (+34.70%) | Filing |
| 2022-01-27 1:59 pm Unchanged | 2021-12-31 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 26,671,803 14.500% | 0 (Unchanged) | Filing |
| 2022-01-25 6:45 pm Purchase | 2021-12-31 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 26,671,803 14.500% | 8,293,723 (+45.13%) | Filing |
| 2021-01-26 6:52 pm Sale | 2020-12-31 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 18,378,080 10.200% | -39,455 (-0.21%) | Filing |